These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33260063)

  • 21. Multicenter clinical trial to evaluate the therapeutic use of recombinant growth hormone from mammalian cells in the treatment of growth hormone neurosecretory dysfunction.
    Hernández M; Nieto JA; Sobradillo B; Pombo M; Ferrández A; Rejas J
    Horm Res; 1991; 35(1):13-8. PubMed ID: 1916648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
    Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
    Höybye C; Beck-Peccoz P; Murray RD; Simsek S; Stalla G; Strasburger CJ; Urosevic D; Zouater H; Johannsson G
    Pituitary; 2021 Aug; 24(4):622-629. PubMed ID: 33742320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of first-year growth response to a fixed-dose growth hormone treatment in children born small for gestational age: results of an open-label, multicenter trial in the United States.
    Rapaport R; Saenger P; Wajnrajch MP;
    J Pediatr Endocrinol Metab; 2008 May; 21(5):411-22. PubMed ID: 18655522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
    Horikawa R; Tanaka T; Hasegawa Y; Yorifuji T; Ng D; Rosenfeld RG; Hoshino Y; Okayama A; Shima D; Gomez R; Pastrak A; Castellanos O
    Horm Res Paediatr; 2022; 95(3):275-285. PubMed ID: 35417909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
    Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant growth hormone in children and adolescents with Turner syndrome.
    Cave CB; Bryant J; Milne R
    Cochrane Database Syst Rev; 2003; (3):CD003887. PubMed ID: 12917993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of peripubertal children after renal transplantation (RTX) with recombinant human growth hormone: auxological data and effects on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during 24 months.
    Riedl S; Lebl J; Kluge M; Kreisinger J; Simková E; Kohlhauser C; Balzar E; Frisch H
    J Pediatr Endocrinol Metab; 1998; 11(6):713-8. PubMed ID: 9829225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study.
    Jung H; Land C; Nicolay C; De Schepper J; Blum WF; Schönau E
    Eur J Endocrinol; 2009 Feb; 160(2):149-56. PubMed ID: 19039085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful switch from originator to biosimilar growth hormone: patients' experiences].
    van Vlijmen B; van Gool L; Repping-Wuts H; Ketels T; Kerstens M; Burger D; Hermus A; Smit J
    Ned Tijdschr Geneeskd; 2017; 161():D1415. PubMed ID: 29098966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
    Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients.
    Sıklar Z; Öcal G; Berberoğlu M; Bilir P
    J Clin Res Pediatr Endocrinol; 2009; 1(5):240-3. PubMed ID: 21274301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
    Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement.
    Kennedy MJ; Davis DA; Smith N; Gaedigk A; Pearce RE; Kearns GL
    Clin Ther; 2008 Sep; 30(9):1687-99. PubMed ID: 18840375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal characteristics and first year responses to human growth hormone (GH) vary according to diagnostic criteria in children with non-acquired GH deficiency (naGHD): observations from a single center over a period of five decades.
    Ranke MB; Schweizer R; Binder G
    J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1257-1266. PubMed ID: 30332395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
    Maniatis AK; Casella SJ; Nadgir UM; Hofman PL; Saenger P; Chertock ED; Aghajanova EM; Korpal-Szczyrska M; Vlachopapadopoulou E; Malievskiy O; Chaychenko T; Cappa M; Song W; Mao M; Mygind PH; Smith AR; Chessler SD; Komirenko AS; Beckert M; Shu AD; Thornton PS
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2680-e2689. PubMed ID: 35428884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.